Aduro’s three proprietary technology platforms (STING Pathway Activators, B-select monoclonal antibodies and Live, Attenuated Double-Deleted Listeria (LADD)) have the potential to transform the current immunotherapy and cancer care landscape.

Aduro is developing novel therapies that are designed to induce highly targeted, potent and sustained immune responses against a variety of cancers. Through our STING Pathway Activator, B-select and LADD platforms, we are poised to fulfill our mission to stay at the forefront of discovery, development and commercialization of immunotherapies, alone or in combination, that have the potential to make transformative advances in the treatment of challenging diseases.

In addition, Aduro has established significant collaboration agreements with leading pharmaceutical and research institutions for each of its platform technologies, further validating the strength and depth of Aduro’s capabilities.

STING Platform

B-select Platform

LADD Platform